| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 47 | 2022 | 1177 | 6.860 |
Why?
|
| Pancreatitis | 41 | 2023 | 1092 | 5.730 |
Why?
|
| Pancreatitis, Chronic | 37 | 2024 | 285 | 4.450 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 27 | 2022 | 437 | 3.280 |
Why?
|
| Exocrine Pancreatic Insufficiency | 7 | 2024 | 80 | 2.420 |
Why?
|
| Gastrointestinal Diseases | 9 | 2022 | 1170 | 2.190 |
Why?
|
| Docosahexaenoic Acids | 18 | 2019 | 875 | 1.900 |
Why?
|
| Enteral Nutrition | 11 | 2023 | 763 | 1.800 |
Why?
|
| Lipase | 6 | 2023 | 314 | 1.600 |
Why?
|
| Hypertriglyceridemia | 4 | 2023 | 293 | 1.510 |
Why?
|
| Pancreas | 15 | 2023 | 1686 | 1.290 |
Why?
|
| Fatty Acids | 14 | 2021 | 1809 | 1.190 |
Why?
|
| Arachidonic Acid | 6 | 2019 | 434 | 0.970 |
Why?
|
| Acute Disease | 30 | 2024 | 7149 | 0.930 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2023 | 1344 | 0.880 |
Why?
|
| Gastroenterology | 2 | 2020 | 536 | 0.870 |
Why?
|
| Bile Ducts | 4 | 2012 | 284 | 0.860 |
Why?
|
| Abdominal Pain | 11 | 2023 | 1063 | 0.810 |
Why?
|
| Infant, Premature | 7 | 2022 | 2044 | 0.790 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2019 | 546 | 0.780 |
Why?
|
| Milk, Human | 5 | 2022 | 490 | 0.760 |
Why?
|
| Pancreatic Function Tests | 7 | 2017 | 69 | 0.730 |
Why?
|
| Triglycerides | 6 | 2023 | 2454 | 0.630 |
Why?
|
| Inservice Training | 2 | 2017 | 392 | 0.630 |
Why?
|
| Pancreatectomy | 3 | 2017 | 804 | 0.620 |
Why?
|
| Fats | 1 | 2018 | 102 | 0.610 |
Why?
|
| Liver Diseases | 2 | 2019 | 1253 | 0.610 |
Why?
|
| Infant Nutritional Physiological Phenomena | 3 | 2022 | 347 | 0.600 |
Why?
|
| Pancreatic Diseases | 1 | 2019 | 350 | 0.590 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 78 | 0.580 |
Why?
|
| Food, Formulated | 1 | 2017 | 109 | 0.580 |
Why?
|
| Linoleic Acid | 5 | 2010 | 157 | 0.570 |
Why?
|
| Gastrointestinal Tract | 3 | 2018 | 814 | 0.560 |
Why?
|
| Lipids | 5 | 2020 | 3305 | 0.510 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2007 | 159 | 0.460 |
Why?
|
| Intestines | 3 | 2020 | 1924 | 0.460 |
Why?
|
| Ileum | 5 | 2020 | 565 | 0.440 |
Why?
|
| Nose | 1 | 2016 | 509 | 0.440 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5256 | 0.430 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 8 | 2022 | 504 | 0.420 |
Why?
|
| Secretin | 3 | 2017 | 57 | 0.410 |
Why?
|
| Hyperoxia | 1 | 2014 | 262 | 0.410 |
Why?
|
| Humans | 147 | 2024 | 744343 | 0.410 |
Why?
|
| Lipoxins | 1 | 2014 | 412 | 0.400 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 871 | 0.390 |
Why?
|
| Mice, Inbred CFTR | 7 | 2012 | 19 | 0.380 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 2 | 2007 | 65 | 0.380 |
Why?
|
| Eicosanoids | 2 | 2010 | 279 | 0.370 |
Why?
|
| Colitis | 2 | 2012 | 1170 | 0.370 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2020 | 1634 | 0.370 |
Why?
|
| Lipopolysaccharides | 4 | 2021 | 2216 | 0.350 |
Why?
|
| Aminophenols | 4 | 2022 | 78 | 0.350 |
Why?
|
| Erythrocytes | 2 | 2018 | 2455 | 0.340 |
Why?
|
| Lung Injury | 1 | 2014 | 436 | 0.340 |
Why?
|
| Intestinal Absorption | 2 | 2023 | 420 | 0.340 |
Why?
|
| Medicine | 2 | 2020 | 946 | 0.320 |
Why?
|
| Enterocolitis, Necrotizing | 3 | 2020 | 341 | 0.310 |
Why?
|
| Gallstones | 2 | 2022 | 286 | 0.310 |
Why?
|
| Respiratory Mucosa | 2 | 2010 | 427 | 0.310 |
Why?
|
| Chlorides | 5 | 2022 | 667 | 0.300 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 264 | 0.300 |
Why?
|
| Interleukin-8 | 3 | 2015 | 690 | 0.300 |
Why?
|
| Transcranial Magnetic Stimulation | 6 | 2010 | 1432 | 0.300 |
Why?
|
| Office Visits | 1 | 2011 | 598 | 0.300 |
Why?
|
| Alcoholism | 3 | 2022 | 1906 | 0.300 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 632 | 0.300 |
Why?
|
| Breast Feeding | 3 | 2018 | 1338 | 0.290 |
Why?
|
| Curriculum | 1 | 2020 | 3605 | 0.290 |
Why?
|
| Dietary Fats | 4 | 2020 | 2017 | 0.290 |
Why?
|
| Short Bowel Syndrome | 2 | 2023 | 345 | 0.280 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 251 | 0.280 |
Why?
|
| Disease Management | 3 | 2017 | 2459 | 0.280 |
Why?
|
| Patient Participation | 2 | 2012 | 1457 | 0.270 |
Why?
|
| Recurrence | 15 | 2022 | 8340 | 0.270 |
Why?
|
| Chloride Channels | 2 | 2004 | 227 | 0.260 |
Why?
|
| Mutation | 18 | 2022 | 29786 | 0.260 |
Why?
|
| Trans-Activators | 3 | 2004 | 2924 | 0.260 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2006 | 227 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 7279 | 0.250 |
Why?
|
| Quality Improvement | 3 | 2019 | 3749 | 0.250 |
Why?
|
| Benchmarking | 1 | 2011 | 1042 | 0.250 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 1863 | 0.250 |
Why?
|
| PPAR alpha | 1 | 2006 | 197 | 0.250 |
Why?
|
| Autoimmune Diseases | 3 | 2018 | 2133 | 0.240 |
Why?
|
| Delphi Technique | 3 | 2022 | 778 | 0.240 |
Why?
|
| Quinolones | 3 | 2022 | 367 | 0.240 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 18029 | 0.240 |
Why?
|
| Colon | 3 | 2009 | 1772 | 0.240 |
Why?
|
| Insulin | 2 | 2022 | 6580 | 0.240 |
Why?
|
| Male | 67 | 2023 | 350118 | 0.230 |
Why?
|
| Pancrelipase | 1 | 2023 | 7 | 0.230 |
Why?
|
| Sweat | 5 | 2010 | 49 | 0.230 |
Why?
|
| Phospholipids | 2 | 2007 | 784 | 0.230 |
Why?
|
| Adult | 43 | 2023 | 214055 | 0.230 |
Why?
|
| Dietary Supplements | 3 | 2019 | 3297 | 0.230 |
Why?
|
| Pancreatitis, Alcoholic | 2 | 2022 | 30 | 0.230 |
Why?
|
| Dextran Sulfate | 3 | 2012 | 236 | 0.220 |
Why?
|
| Swine | 6 | 2023 | 5917 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 2 | 2022 | 706 | 0.220 |
Why?
|
| Child | 27 | 2022 | 77709 | 0.220 |
Why?
|
| Animals | 34 | 2023 | 168757 | 0.220 |
Why?
|
| Retinopathy of Prematurity | 2 | 2022 | 421 | 0.220 |
Why?
|
| Lung | 6 | 2022 | 9856 | 0.210 |
Why?
|
| Animals, Newborn | 6 | 2021 | 2726 | 0.210 |
Why?
|
| Female | 65 | 2023 | 380194 | 0.210 |
Why?
|
| Mice, Knockout | 9 | 2018 | 14557 | 0.210 |
Why?
|
| Lipolysis | 1 | 2023 | 210 | 0.210 |
Why?
|
| Nasal Mucosa | 5 | 2010 | 373 | 0.210 |
Why?
|
| Genetic Testing | 3 | 2010 | 3444 | 0.200 |
Why?
|
| Choledocholithiasis | 1 | 2022 | 48 | 0.200 |
Why?
|
| Needs Assessment | 2 | 2017 | 1147 | 0.200 |
Why?
|
| Food, Fortified | 1 | 2022 | 191 | 0.200 |
Why?
|
| Decision Making | 2 | 2012 | 3887 | 0.200 |
Why?
|
| Postprandial Period | 1 | 2003 | 292 | 0.200 |
Why?
|
| Infant, Newborn | 11 | 2022 | 25625 | 0.200 |
Why?
|
| Electric Stimulation Therapy | 4 | 2009 | 605 | 0.190 |
Why?
|
| Consensus | 2 | 2023 | 2959 | 0.190 |
Why?
|
| Analgesics, Opioid | 7 | 2022 | 3674 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 2759 | 0.190 |
Why?
|
| Prospective Studies | 15 | 2023 | 53288 | 0.190 |
Why?
|
| Oxylipins | 1 | 2021 | 49 | 0.190 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2015 | 503 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2011 | 1886 | 0.190 |
Why?
|
| Pain | 8 | 2022 | 4986 | 0.190 |
Why?
|
| Hydrolysis | 2 | 2017 | 682 | 0.190 |
Why?
|
| Chymotrypsin | 2 | 2017 | 149 | 0.190 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 422 | 0.180 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2023 | 360 | 0.180 |
Why?
|
| Infant | 11 | 2022 | 35136 | 0.180 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2019 | 31 | 0.180 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2019 | 7 | 0.180 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2019 | 57 | 0.180 |
Why?
|
| Injections, Subcutaneous | 2 | 2019 | 666 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2007 | 9648 | 0.170 |
Why?
|
| Fatty Acids, Essential | 1 | 2020 | 95 | 0.170 |
Why?
|
| Trypsin | 2 | 2017 | 511 | 0.170 |
Why?
|
| Infant Formula | 2 | 2016 | 199 | 0.170 |
Why?
|
| Adolescent | 21 | 2022 | 85781 | 0.170 |
Why?
|
| Liver | 3 | 2012 | 7474 | 0.170 |
Why?
|
| Arachidonic Acids | 1 | 2019 | 299 | 0.170 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 417 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5751 | 0.170 |
Why?
|
| Deep Brain Stimulation | 4 | 2007 | 748 | 0.170 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 426 | 0.160 |
Why?
|
| Restless Legs Syndrome | 1 | 2022 | 228 | 0.160 |
Why?
|
| Mice | 20 | 2020 | 81183 | 0.160 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 163 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1677 | 0.160 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2018 | 59 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 3229 | 0.160 |
Why?
|
| Child, Preschool | 13 | 2021 | 41006 | 0.160 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2022 | 306 | 0.160 |
Why?
|
| Apolipoprotein C-III | 1 | 2019 | 202 | 0.160 |
Why?
|
| Carrier Proteins | 4 | 2016 | 5021 | 0.160 |
Why?
|
| Infusions, Subcutaneous | 1 | 2017 | 42 | 0.160 |
Why?
|
| Peptide YY | 1 | 2018 | 130 | 0.160 |
Why?
|
| RNA, Messenger | 5 | 2019 | 13033 | 0.160 |
Why?
|
| Intestinal Mucosa | 4 | 2020 | 3036 | 0.150 |
Why?
|
| Communication | 1 | 2011 | 3749 | 0.150 |
Why?
|
| Quality of Life | 8 | 2024 | 12804 | 0.150 |
Why?
|
| Bicarbonates | 2 | 2017 | 313 | 0.150 |
Why?
|
| Chronic Disease | 12 | 2020 | 9146 | 0.150 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2020 | 321 | 0.150 |
Why?
|
| Heterozygote | 4 | 2004 | 2804 | 0.150 |
Why?
|
| Pancreatic Juice | 1 | 2017 | 62 | 0.150 |
Why?
|
| Jaundice, Obstructive | 1 | 2017 | 20 | 0.150 |
Why?
|
| Fish Oils | 1 | 2021 | 470 | 0.150 |
Why?
|
| Transcription Factors | 4 | 2004 | 12208 | 0.150 |
Why?
|
| Endosonography | 2 | 2020 | 610 | 0.150 |
Why?
|
| Critical Pathways | 2 | 2018 | 476 | 0.150 |
Why?
|
| Retrospective Studies | 18 | 2023 | 77449 | 0.150 |
Why?
|
| Polysaccharides | 2 | 2020 | 1053 | 0.140 |
Why?
|
| Cross-Over Studies | 3 | 2017 | 2029 | 0.140 |
Why?
|
| Disease Progression | 6 | 2022 | 13284 | 0.140 |
Why?
|
| Registries | 4 | 2023 | 8089 | 0.140 |
Why?
|
| Oligonucleotides | 1 | 2019 | 572 | 0.140 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 2065 | 0.140 |
Why?
|
| Hospitalization | 7 | 2023 | 10262 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2017 | 582 | 0.130 |
Why?
|
| Isoproterenol | 2 | 2007 | 399 | 0.130 |
Why?
|
| Length of Stay | 7 | 2023 | 6309 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2007 | 2958 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2012 | 4468 | 0.130 |
Why?
|
| Mice, Transgenic | 6 | 2019 | 9734 | 0.130 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2022 | 868 | 0.130 |
Why?
|
| Malabsorption Syndromes | 1 | 2016 | 135 | 0.130 |
Why?
|
| Mucin 5AC | 1 | 2015 | 93 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 972 | 0.130 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 2 | 2016 | 30 | 0.130 |
Why?
|
| Middle Aged | 27 | 2023 | 213383 | 0.130 |
Why?
|
| Brain | 6 | 2019 | 26385 | 0.130 |
Why?
|
| Ion Transport | 2 | 2007 | 320 | 0.130 |
Why?
|
| Monocytes | 1 | 2004 | 2596 | 0.130 |
Why?
|
| Eating | 1 | 2022 | 1536 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 1676 | 0.120 |
Why?
|
| Organoids | 1 | 2020 | 701 | 0.120 |
Why?
|
| Research | 1 | 2023 | 1999 | 0.120 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2010 | 768 | 0.120 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2003 | 2839 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 3022 | 0.120 |
Why?
|
| Neuronal Plasticity | 2 | 2016 | 1422 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2018 | 492 | 0.120 |
Why?
|
| Cadherins | 1 | 2019 | 907 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2020 | 1241 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 9 | 2020 | 21827 | 0.120 |
Why?
|
| Biomedical Research | 3 | 2021 | 3309 | 0.120 |
Why?
|
| Young Adult | 11 | 2022 | 56430 | 0.120 |
Why?
|
| Pancreaticojejunostomy | 1 | 2013 | 26 | 0.120 |
Why?
|
| Metabolome | 1 | 2020 | 895 | 0.120 |
Why?
|
| Drainage | 2 | 2020 | 1142 | 0.120 |
Why?
|
| Energy Intake | 2 | 2023 | 2148 | 0.120 |
Why?
|
| Evoked Potentials, Motor | 1 | 2016 | 454 | 0.110 |
Why?
|
| Genotype | 7 | 2019 | 12951 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2023 | 1580 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2019 | 4751 | 0.110 |
Why?
|
| Double-Blind Method | 6 | 2019 | 12026 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2017 | 2107 | 0.110 |
Why?
|
| Membrane Potentials | 3 | 2010 | 1137 | 0.110 |
Why?
|
| Pancreatic Elastase | 2 | 2022 | 136 | 0.110 |
Why?
|
| Adipocytes | 1 | 2019 | 1184 | 0.110 |
Why?
|
| Amylases | 1 | 2012 | 173 | 0.110 |
Why?
|
| Body Composition | 1 | 2022 | 2401 | 0.110 |
Why?
|
| Time Factors | 11 | 2018 | 40075 | 0.110 |
Why?
|
| Risk Factors | 16 | 2024 | 72290 | 0.100 |
Why?
|
| Benzodioxoles | 2 | 2022 | 69 | 0.100 |
Why?
|
| Health Care Costs | 2 | 2016 | 3209 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2003 | 3023 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2023 | 8324 | 0.100 |
Why?
|
| Patient Care | 1 | 2017 | 640 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 5853 | 0.100 |
Why?
|
| Early Diagnosis | 3 | 2015 | 1184 | 0.100 |
Why?
|
| Case-Control Studies | 7 | 2022 | 21746 | 0.100 |
Why?
|
| Neonatal Screening | 2 | 2009 | 591 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2018 | 1530 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 1179 | 0.100 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 675 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2004 | 627 | 0.100 |
Why?
|
| Pediatrics | 2 | 2017 | 3475 | 0.100 |
Why?
|
| Cell Count | 2 | 2008 | 1856 | 0.100 |
Why?
|
| Cohort Studies | 10 | 2022 | 40561 | 0.100 |
Why?
|
| Severity of Illness Index | 8 | 2023 | 15540 | 0.100 |
Why?
|
| Protein Conformation | 3 | 2003 | 4011 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2023 | 1947 | 0.100 |
Why?
|
| Peptides | 1 | 2003 | 4409 | 0.090 |
Why?
|
| Aged | 18 | 2023 | 163280 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 2 | 2010 | 1526 | 0.090 |
Why?
|
| Treatment Outcome | 13 | 2022 | 63114 | 0.090 |
Why?
|
| Trypsinogen | 1 | 2010 | 86 | 0.090 |
Why?
|
| Pneumonia | 1 | 2002 | 2133 | 0.090 |
Why?
|
| Morbidity | 1 | 2015 | 1769 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2023 | 3313 | 0.090 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 1643 | 0.090 |
Why?
|
| Emulsions | 2 | 2021 | 156 | 0.090 |
Why?
|
| Emergency Service, Hospital | 5 | 2023 | 7659 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2022 | 3279 | 0.090 |
Why?
|
| Feces | 1 | 2016 | 1401 | 0.090 |
Why?
|
| Radiology | 1 | 2023 | 2100 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2016 | 985 | 0.090 |
Why?
|
| Access to Information | 1 | 2012 | 320 | 0.080 |
Why?
|
| Administration, Oral | 4 | 2006 | 3913 | 0.080 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 336 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 3966 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 1831 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2003 | 5456 | 0.080 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2009 | 110 | 0.080 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2008 | 37 | 0.080 |
Why?
|
| Respiratory Therapy | 1 | 2009 | 132 | 0.080 |
Why?
|
| Bronchiectasis | 1 | 2009 | 128 | 0.080 |
Why?
|
| Prevalence | 5 | 2019 | 15226 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 367 | 0.080 |
Why?
|
| Bile Acids and Salts | 2 | 2023 | 367 | 0.080 |
Why?
|
| Hematocrit | 1 | 2009 | 636 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2012 | 1100 | 0.080 |
Why?
|
| Age Factors | 4 | 2019 | 18370 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2019 | 7722 | 0.080 |
Why?
|
| United States | 8 | 2023 | 69872 | 0.080 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2007 | 60 | 0.080 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2009 | 161 | 0.080 |
Why?
|
| Nutritional Support | 1 | 2009 | 168 | 0.080 |
Why?
|
| Cholecystectomy | 2 | 2020 | 395 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2017 | 12959 | 0.070 |
Why?
|
| Pain Measurement | 5 | 2020 | 3420 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 11725 | 0.070 |
Why?
|
| Somatosensory Cortex | 2 | 2010 | 528 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2022 | 12720 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2371 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2010 | 3760 | 0.070 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2007 | 101 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2003 | 13815 | 0.070 |
Why?
|
| Prognosis | 7 | 2023 | 29063 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2009 | 1850 | 0.070 |
Why?
|
| Inflammation | 3 | 2023 | 10638 | 0.070 |
Why?
|
| Random Allocation | 3 | 2019 | 2429 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2007 | 150 | 0.070 |
Why?
|
| Visceral Afferents | 1 | 2005 | 9 | 0.070 |
Why?
|
| Pyridines | 2 | 2022 | 2825 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2022 | 1959 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2009 | 537 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 908 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 18111 | 0.070 |
Why?
|
| Analgesia | 1 | 2010 | 461 | 0.070 |
Why?
|
| Viscera | 1 | 2006 | 139 | 0.070 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 3507 | 0.070 |
Why?
|
| Medicare | 1 | 2023 | 6566 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 4186 | 0.070 |
Why?
|
| Organelles | 1 | 2007 | 264 | 0.070 |
Why?
|
| Delirium | 1 | 2017 | 1609 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2006 | 361 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2006 | 1572 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 3778 | 0.060 |
Why?
|
| Exercise | 1 | 2022 | 5615 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 2872 | 0.060 |
Why?
|
| Cerebral Cortex | 3 | 2006 | 5708 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 11366 | 0.060 |
Why?
|
| Ion Channels | 2 | 2010 | 1056 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 454 | 0.060 |
Why?
|
| Fluid Therapy | 2 | 2019 | 593 | 0.060 |
Why?
|
| Cell Line | 5 | 2015 | 15997 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5172 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 561 | 0.060 |
Why?
|
| Pyramidal Tracts | 1 | 2006 | 256 | 0.060 |
Why?
|
| Bronchi | 1 | 2008 | 840 | 0.060 |
Why?
|
| Critical Illness | 1 | 2017 | 2670 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3610 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 57776 | 0.060 |
Why?
|
| Forced Expiratory Volume | 2 | 2010 | 1743 | 0.060 |
Why?
|
| Creatinine | 1 | 2009 | 1919 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 12072 | 0.060 |
Why?
|
| Pulmonary Surfactants | 1 | 2004 | 162 | 0.060 |
Why?
|
| Patient Readmission | 3 | 2023 | 3114 | 0.060 |
Why?
|
| Pregnancy, Animal | 1 | 2004 | 134 | 0.060 |
Why?
|
| Qc-SNARE Proteins | 1 | 2003 | 21 | 0.060 |
Why?
|
| Qb-SNARE Proteins | 1 | 2003 | 36 | 0.060 |
Why?
|
| Pancreatic Hormones | 1 | 2022 | 13 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2008 | 19229 | 0.060 |
Why?
|
| Circular Dichroism | 1 | 2003 | 354 | 0.060 |
Why?
|
| Pinealoma | 1 | 2003 | 54 | 0.060 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 25043 | 0.050 |
Why?
|
| Muscarinic Agonists | 1 | 2003 | 87 | 0.050 |
Why?
|
| PPAR gamma | 1 | 2006 | 493 | 0.050 |
Why?
|
| Carbachol | 1 | 2003 | 226 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7785 | 0.050 |
Why?
|
| Diet | 2 | 2016 | 7939 | 0.050 |
Why?
|
| Protein Binding | 3 | 2004 | 9386 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2010 | 1219 | 0.050 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2003 | 97 | 0.050 |
Why?
|
| Cholecystokinin | 1 | 2003 | 114 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4838 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 4420 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2015 | 2348 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2009 | 1184 | 0.050 |
Why?
|
| Chemokine CXCL2 | 1 | 2002 | 111 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 17446 | 0.050 |
Why?
|
| Microscopy | 1 | 2007 | 903 | 0.050 |
Why?
|
| Signal Transduction | 4 | 2019 | 23403 | 0.050 |
Why?
|
| Fibromyalgia | 1 | 2006 | 388 | 0.050 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2004 | 209 | 0.050 |
Why?
|
| Chemokine CXCL1 | 1 | 2002 | 101 | 0.050 |
Why?
|
| Chromatography, Thin Layer | 1 | 2002 | 223 | 0.050 |
Why?
|
| Pineal Gland | 1 | 2003 | 166 | 0.050 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2012 | 1209 | 0.050 |
Why?
|
| Amniotic Fluid | 1 | 2004 | 370 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2002 | 117 | 0.050 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2022 | 109 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2022 | 73 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 12354 | 0.050 |
Why?
|
| Antiporters | 1 | 2003 | 277 | 0.050 |
Why?
|
| Functional Laterality | 2 | 2005 | 2290 | 0.050 |
Why?
|
| Chemotactic Factors | 1 | 2002 | 199 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 2278 | 0.050 |
Why?
|
| Electrolytes | 1 | 2002 | 282 | 0.050 |
Why?
|
| Cortical Spreading Depression | 1 | 2005 | 276 | 0.050 |
Why?
|
| Immunity | 1 | 2007 | 1012 | 0.050 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2003 | 689 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2019 | 6365 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 476 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 565 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 1970 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2018 | 5078 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 592 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 316 | 0.050 |
Why?
|
| Mucin-2 | 1 | 2020 | 49 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 419 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 865 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 1312 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2003 | 936 | 0.050 |
Why?
|
| Acetylation | 1 | 2023 | 1085 | 0.050 |
Why?
|
| Swine Diseases | 1 | 2020 | 73 | 0.050 |
Why?
|
| Lung Transplantation | 1 | 2009 | 1153 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2003 | 507 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 1454 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 7181 | 0.050 |
Why?
|
| Microvilli | 1 | 2020 | 241 | 0.050 |
Why?
|
| Corn Oil | 1 | 2019 | 29 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2007 | 1357 | 0.040 |
Why?
|
| Prednisone | 1 | 2005 | 1574 | 0.040 |
Why?
|
| Inpatients | 2 | 2022 | 2518 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 387 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2022 | 342 | 0.040 |
Why?
|
| Protein Folding | 1 | 2003 | 843 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2005 | 1767 | 0.040 |
Why?
|
| Growth Substances | 1 | 2002 | 784 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2020 | 1609 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2002 | 390 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 15076 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2003 | 1246 | 0.040 |
Why?
|
| Aerosols | 1 | 2002 | 625 | 0.040 |
Why?
|
| Neuralgia | 1 | 2006 | 570 | 0.040 |
Why?
|
| Animal Feed | 1 | 2019 | 110 | 0.040 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 39050 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 613 | 0.040 |
Why?
|
| Homozygote | 1 | 2004 | 1785 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 3396 | 0.040 |
Why?
|
| Zinc | 1 | 2003 | 684 | 0.040 |
Why?
|
| International Cooperation | 2 | 2017 | 1420 | 0.040 |
Why?
|
| Movement | 1 | 2006 | 1471 | 0.040 |
Why?
|
| Ethanol | 1 | 2005 | 1342 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 841 | 0.040 |
Why?
|
| Rectum | 1 | 2004 | 904 | 0.040 |
Why?
|
| Sodium | 1 | 2004 | 1623 | 0.040 |
Why?
|
| Demography | 2 | 2019 | 1656 | 0.040 |
Why?
|
| Body Weight | 2 | 2017 | 4669 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2004 | 2425 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 1 | 2020 | 251 | 0.040 |
Why?
|
| Single-Blind Method | 3 | 2006 | 1590 | 0.040 |
Why?
|
| Permeability | 1 | 2020 | 738 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2002 | 1263 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2003 | 2256 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2003 | 2011 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2020 | 3689 | 0.040 |
Why?
|
| Spinal Cord Injuries | 1 | 2006 | 931 | 0.040 |
Why?
|
| Constipation | 1 | 2022 | 546 | 0.040 |
Why?
|
| Databases, Factual | 3 | 2019 | 7729 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2022 | 545 | 0.040 |
Why?
|
| Indomethacin | 1 | 2018 | 332 | 0.040 |
Why?
|
| Chemokines | 1 | 2002 | 970 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2004 | 1183 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2023 | 817 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2022 | 1173 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2020 | 287 | 0.040 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2017 | 60 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2019 | 328 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13695 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 1901 | 0.040 |
Why?
|
| Sepsis | 1 | 2011 | 2593 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2017 | 141 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2004 | 3002 | 0.040 |
Why?
|
| Israel | 1 | 2019 | 796 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2022 | 1462 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 781 | 0.040 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 209 | 0.040 |
Why?
|
| Models, Animal | 2 | 2019 | 2171 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2004 | 5179 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 345 | 0.040 |
Why?
|
| Reference Values | 1 | 2004 | 4982 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2004 | 6622 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2018 | 370 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 961 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 931 | 0.030 |
Why?
|
| Micelles | 1 | 2017 | 203 | 0.030 |
Why?
|
| Australia | 1 | 2019 | 1170 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 2020 | 650 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2011 | 4687 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2007 | 2921 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 12745 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 723 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3690 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 14722 | 0.030 |
Why?
|
| Exons | 1 | 2002 | 2437 | 0.030 |
Why?
|
| Action Potentials | 1 | 2003 | 1806 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 1725 | 0.030 |
Why?
|
| Body Fluids | 1 | 2017 | 319 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1249 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2023 | 2263 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 1990 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2020 | 9849 | 0.030 |
Why?
|
| Prodrugs | 1 | 2017 | 268 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2866 | 0.030 |
Why?
|
| Ovary | 1 | 2019 | 981 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2017 | 15295 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2007 | 2657 | 0.030 |
Why?
|
| Resuscitation | 1 | 2019 | 658 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 2158 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2018 | 570 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2020 | 10481 | 0.030 |
Why?
|
| Duodenum | 1 | 2017 | 483 | 0.030 |
Why?
|
| Phenotype | 2 | 2020 | 16365 | 0.030 |
Why?
|
| Canada | 1 | 2019 | 2065 | 0.030 |
Why?
|
| Counseling | 1 | 2022 | 1523 | 0.030 |
Why?
|
| Indoles | 1 | 2022 | 1839 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 2016 | 409 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3768 | 0.030 |
Why?
|
| Postnatal Care | 1 | 2015 | 236 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 10943 | 0.030 |
Why?
|
| Cisplatin | 1 | 2019 | 1662 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6171 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 1889 | 0.030 |
Why?
|
| Stroke | 2 | 2006 | 9981 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2014 | 270 | 0.030 |
Why?
|
| Smoking | 2 | 2023 | 8987 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6314 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3557 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 494 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 847 | 0.030 |
Why?
|
| Weight Gain | 1 | 2022 | 2292 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2017 | 604 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 638 | 0.030 |
Why?
|
| Biopsy | 1 | 2004 | 6756 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 850 | 0.030 |
Why?
|
| Patient Preference | 1 | 2019 | 890 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2022 | 1972 | 0.020 |
Why?
|
| Multipotent Stem Cells | 1 | 2012 | 186 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 1889 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2003 | 4217 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2503 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2023 | 5985 | 0.020 |
Why?
|
| Age of Onset | 1 | 2017 | 3271 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 1405 | 0.020 |
Why?
|
| Epilepsy | 1 | 2006 | 3310 | 0.020 |
Why?
|
| Bone Density | 1 | 2023 | 3468 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1200 | 0.020 |
Why?
|
| Neutrophils | 1 | 2002 | 3719 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 1681 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2019 | 6459 | 0.020 |
Why?
|
| Premature Birth | 1 | 2020 | 1721 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2010 | 576 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2003 | 6544 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2002 | 4286 | 0.020 |
Why?
|
| Incidence | 2 | 2017 | 20947 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 3617 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3586 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3158 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 2569 | 0.020 |
Why?
|
| Mice, Congenic | 1 | 2006 | 99 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 23338 | 0.020 |
Why?
|
| Gestational Age | 1 | 2015 | 3493 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 601 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 2499 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2016 | 1859 | 0.020 |
Why?
|
| Arm | 1 | 2009 | 589 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10252 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 2031 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20129 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2003 | 7880 | 0.020 |
Why?
|
| Sleep | 1 | 2022 | 4623 | 0.020 |
Why?
|
| Oleic Acids | 1 | 2005 | 70 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 5319 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2017 | 2531 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 7322 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10397 | 0.020 |
Why?
|
| Salivary Glands | 1 | 2006 | 229 | 0.020 |
Why?
|
| Stents | 1 | 2017 | 3280 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 498 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 425 | 0.020 |
Why?
|
| Asthma | 1 | 2004 | 6011 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4560 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 2453 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2005 | 237 | 0.020 |
Why?
|
| Indole Alkaloids | 1 | 2004 | 24 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2010 | 1169 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 19905 | 0.020 |
Why?
|
| Esters | 1 | 2005 | 210 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13989 | 0.020 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2004 | 38 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 8428 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 4201 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 868 | 0.020 |
Why?
|
| Apoptosis | 1 | 2020 | 9727 | 0.020 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2004 | 131 | 0.010 |
Why?
|
| Neural Conduction | 1 | 2005 | 440 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2004 | 554 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12245 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 876 | 0.010 |
Why?
|
| Hypertonic Solutions | 1 | 2003 | 93 | 0.010 |
Why?
|
| Plasma | 1 | 2006 | 575 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2538 | 0.010 |
Why?
|
| Chloride-Bicarbonate Antiporters | 1 | 2003 | 103 | 0.010 |
Why?
|
| Electrodes | 1 | 2005 | 619 | 0.010 |
Why?
|
| Digestive System | 1 | 2004 | 253 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 16689 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2005 | 536 | 0.010 |
Why?
|
| Nociceptors | 1 | 2006 | 432 | 0.010 |
Why?
|
| Disulfides | 1 | 2004 | 457 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 733 | 0.010 |
Why?
|
| Boston | 1 | 2015 | 9313 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2006 | 502 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 8863 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2004 | 675 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2005 | 1901 | 0.010 |
Why?
|
| Xenopus | 1 | 2003 | 712 | 0.010 |
Why?
|
| Hand | 1 | 2006 | 884 | 0.010 |
Why?
|
| Electroencephalography | 2 | 2006 | 6150 | 0.010 |
Why?
|
| DNA | 1 | 2014 | 7301 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2006 | 1609 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2004 | 726 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2003 | 1472 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2003 | 1266 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 3582 | 0.010 |
Why?
|
| Research Design | 1 | 2014 | 5987 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 21683 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 1539 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9687 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 2557 | 0.010 |
Why?
|
| Models, Biological | 2 | 2006 | 9583 | 0.010 |
Why?
|
| Oocytes | 1 | 2003 | 1187 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2006 | 1809 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 5882 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 8642 | 0.010 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 2147 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 2382 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2006 | 1916 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 1348 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 3846 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2003 | 2564 | 0.010 |
Why?
|
| Seizures | 1 | 2006 | 2859 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 3508 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 2541 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2004 | 2214 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 7913 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 7799 | 0.010 |
Why?
|
| Cognition | 1 | 2006 | 6770 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 24260 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 4253 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 29144 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 11124 | 0.000 |
Why?
|